Laura Stoppel - Jun 4, 2025 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director
Signature
/s/ Derek Meisner, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/5/2025, 06:05 PM
Previous filing
Jul 18, 2024
Next filing
Jun 26, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stoppel Laura Director C/O RA CAPITAL MANAGEMENT, 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Derek Meisner, Attorney-in-Fact 2025-06-05 0001865119

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Award $0 +12.8K $0.00 12.8K Jun 4, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Stock Option (right to buy) Award $0 +19.5K $0.00 19.5K Jun 4, 2025 Common Stock 19.5K $1.07 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
F3 The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.